Gazyvaro: new targeted lymphoma treatment

Obinutuzumab (Gazyvaro) is licensed for previously untreated chronic lymphocytic lymphoma (CLL) in patients who are ineligible for intensive therapy with full-dose fludarabine.

Patients should receive premedication with an analgesic, antihistamine and intravenous corticosteroid before each infusion.
Patients should receive premedication with an analgesic, antihistamine and intravenous corticosteroid before each infusion.


Obinutuzumab is a monoclonal antibody that targets the CD20 antigen on the surface of B-lymphocytes, inducing direct cell death and mediating antibody-dependent cellular cytotoxicity, with less complement-dependent cytotoxicity than rituximab (another CD20-targeting antibody).1,2


The efficacy of obinutuzumab in combination with chlorambucil was compared with that of rituximab plus chlorambucil and chlorambucil monotherapy in 781 patients with previously untreated CLL who also had a co-existing condition (defined as a score of 6 or higher on the Cumulative Illness Rating Scale [CIRS] or a creatinine clearance of 30–69ml/min).2

Obinutuzumab plus chlorambucil was superior to both chlorambucil monotherapy and rituximab plus chlorambucil, with median progression-free survival of 26.7 months compared with 11.1 months and 16.3 months, respectively (p<0.001 for both comparisons).2

Infusion-related reactions and neutropenia were more common with obinutuzumab–chlorambucil than with rituximab–chlorambucil, but the risk of infection was not increased.2


  1. Gazyvaro Summary of Product Characteristics, July 2014.
  2. Goede V et al. N Engl J Med 2014; 370: 1101–10.

View Gazyvaro drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...